ABSTRACT
OBJECTIVE: Extraovarian peritoneal serous papillary carcinoma (EPSPC) is both histologically and clinically similar to stage III-IV ovarian papillary serous carcinoma (OPSC). The purpose of this study is to investigate the clinical findings, treatment, and outcome of EPSPC patients compared with stage III-IV OPSC patients. METHODS: The data of 12 EPSPC patients and 45 stage III-IV OPSC patients were retrospectively reviewed, comparing the characteristics on clinical presentation and treatment, sensitivity to first-line chemotherapy agents and survival. RESULTS: By analysis of patients' characteristics, presenting signs and symptoms, type and extent of surgery, tumor response to first-line chemotherapy, recurrence-free interval, recurrence site and serum CA-125 levels, no significant difference was observed between the EPSPC patients and stage III-IV OPSC controls. The prevailing presenting symptoms were abdominal mass and ascites. The mainstay of treatment was debulking surgery followed by adjuvant platinum-based chemotherapy. The complete clinical response of stage III-IV OPSC was 91.8% compared with 25.0% for women with EPSPC (P < 0.01). CONCLUSION: The clinical and surgical characteristics of EPSPC are similar to those of stage III-IV OPSC. When the same treatment strategy is applied, similar response and survival are expected in either condition.
Subject(s)
Cystadenocarcinoma, Papillary , Ovarian Neoplasms , Peritoneal Neoplasms , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , CA-125 Antigen/blood , Cisplatin/therapeutic use , Combined Modality Therapy , Cyclophosphamide/therapeutic use , Cystadenocarcinoma, Papillary/blood , Cystadenocarcinoma, Papillary/drug therapy , Cystadenocarcinoma, Papillary/pathology , Cystadenocarcinoma, Papillary/surgery , Disease-Free Survival , Doxorubicin/analogs & derivatives , Doxorubicin/therapeutic use , Female , Follow-Up Studies , Humans , Middle Aged , Neoplasm Staging , Ovarian Neoplasms/blood , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/pathology , Ovarian Neoplasms/surgery , Paclitaxel , Peritoneal Neoplasms/blood , Peritoneal Neoplasms/drug therapy , Peritoneal Neoplasms/pathology , Peritoneal Neoplasms/surgery , Retrospective Studies , Taxoids/therapeutic useABSTRACT
OBJECTIVE: This report was to review how extragastrointestinal stromal tumor (EGIST) was similar to ovarian cancer, its differential diagnosis and treatment. METHODS: Three cases of EGIST were reported and discussed by reviewing literatures. RESULTS: The cases of EGIST were presented with peritoneal and pelvic mass, or ascites, diagnosed as ovarian cancer at first, and finally diagnosed as EGIST by pathological method and positive CD(117) and CD(34) expression. Surgery in combination with chemotherapy was an effective therapeutic method. CONCLUSIONS: Clinical presentation of EGIST is similar to ovarian cancer in some aspects. Detection of CD(117) and CD(34) positive expression is helpful in the diagnosis of EGIST.
